Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Fresh Tracks Therapeutics Inc V.BBI


Primary Symbol: FRTX

Fresh Tracks Therapeutics, Inc. is not engaged in any business activities. The Company is in the process of dissolution.


PINL:FRTX - Post by User

Comment by skiptoggleon Jul 26, 2019 11:23am
157 Views
Post# 29964076

RE:RE:Assumptions about future production's impact on share price

RE:RE:Assumptions about future production's impact on share priceThanks Don for the cogent and polite answer.  However, I would point out that of the 209 million fully diluted shares listed on the May presentation 190,000,000 are actual shares, and 19 million are warrants and options.  The bulk of that 19 million delta are warrants which don't count unless they pay the entry fee.  If they warrant holders do exercise their right that would add much needed capital.  Which is why I suggested the 190,000,000 basic shares in any calculation.

Again I assumed no further dilution in my question but there is the possibility that it will be needed to sustain growth beyond 2020.

The elephant in the room is what to warrant holders do if, even in the hypothetical situation, Pipe achieves the 2.82 share price by May 2021?  Do they let their warrents expire or try to make the best of a bad situation by excercising their right to purchase?


Bullboard Posts